Millennium starts Phase II with LDP-02

MLNM began a Canadian Phase II trial study of its LDP-02 humanized monoclonal antibody against the alpha4-beta7 integrin receptor on lymphocytes in 180 patients with ulcerative colitis. The double-bli...